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Abstract   
Objectives: This study assessed the long-term course, remission rate and disease burden in juvenile 
idiopathic arthritis (JIA) 18 years after disease onset in a population-based setting from the early 
biologic era.  
Methods: A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from 
defined geographic regions in Denmark, Norway, Sweden and Finland were prospectively included in 
this 18-year cohort study.  At the follow-up visit, patient-reported, demographic and clinical data 
were collected.   
Results: The study included 434 (85%) of the 510 eligible JIA participants. The mean age ± SD was 
24.0 ± 4.4 years. The median juvenile arthritis disease activity (JADAS71) score was 1.5 (IQR 0-5), 
with the ERA category of JIA having the highest median score, 4.5 (IQR 1.5–8.5) (P=0.003). In this 
cohort, 46% still had active disease, and 66 (15%) were treated with synthetic disease-modifying 
anti-rheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by JADAS71 <1 was seen 
in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the 
participants with high variability among the JIA categories. CR was most often seen in persistent 
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Conclusions: A high prevalence of the JIA cohort did not achieve CR despite new treatment options 
during the study period. The ERA category showed the worst outcomes and, in general, there is still 
a high burden of disease in adulthood for JIA.  
 
SIGNIFICANCE AND INNOVATIONS 
There is an ongoing debate about the long-term outcomes of juvenile idiopathic arthritis (JIA) in the 
biologic era. Some hypothesize that the use of biologics has improved the disease course. 
 
This is the first study to evaluate the long-term outcomes in JIA in a population-based setting. We 
show that:  
 33% were in complete remission off medication 
 46% had active disease although in the mild end of the scale 
 30% received systemic treatment 
 The ERA category had the worst outcomes 
 
The study adds to the evidence that a substantial proportion of patients continue to have active 
disease, and the burden of medication is extensive in JIA, even 18 years after disease onset.  
 
 INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic arthritides with childhood 
onset. Since 1999, the advent of biologics has changed the long-term functional outcome of JIA 
dramatically, and it may no longer be possible to rely on outcome studies from the pre-biologic era. 
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JIA (1,2) sustained clinical remission off all antiarthritic and anti-uveitis medication (CR) is still elusive 
for many. 
During the last two decades, the efficacy and safety of biologic therapy have been studied 
extensively in selected cohorts with short-term follow-up. However, the few observational studies 
with a long-term follow-up that have been conducted in the biologic era, are difficult to compare 
because of differences in the study populations (1,3,4). In recent JIA studies from the biologic era, 
about 21% of patients achieved CR within 5 years after diagnosis, and this proportion increased to 
36% within 10 years of follow-up (5). In a population-based setting, we previously studied the 8-year 
outcome of all JIA categories in the very early biologic era (6). We found that about one-third still 
had intermittently active disease and 49% were not in remission after 8 years of follow-up. Further, 
23% had developed JIA-related damage. The systemic and the oligoarticular persistent categories 
had the best prognosis with 80% and 65% in remission off medication, respectively.  
No previous study from the biologic era was population-based or had follow-up of more than 8 
years.  
This study aims to add to the knowledge base by describing the long-term course, remission rate and 
disease burden of JIA 18 years after disease onset in a population-based setting.  
PATIENTS AND METHODS 
This close to population-based study followed consecutive cases of newly diagnosed JIA from 
defined geographical areas of Denmark, Finland, Norway and Sweden, as described previously (7). 
Inclusion started at disease onset between January 1st, 1997 and June 30th, 2000 (6,7). The baseline 
visit aimed to take place within the first 6 months (-1/+ 2 months) after disease onset. To reflect a 
population-based sample, the study included all consecutively referred patients from geographically 
defined catchment areas in each country. Letters were repeatedly sent to all primary health care 
centers, orthopedic, rheumatology and pediatric clinics in the catchment areas to ensure the referral 
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For the 18-year follow-up, all 510 previously included participants from the Nordic study cohort 
were invited to participate regardless of medical exposure, disease course or activity. For 
participants who were unable to attend a study visit, we offered a standardized telephone interview 
that included electronic completion of the validated health assessment questionnaire (HAQ) (8) and 
visual analogue scales (VASs). Blood samples were collected from all participants that took part in 
the clinical study visit. The study visit included an updated family and medication history. Clinical 
data were collected including a joint examination and blood samples. To verify the participant 
reported data (e.g. in the use of determination of remission status and disease status the previous 
10 years) a crosscheck of the electronical records was performed.  
All participants fulfilling the ILAR criteria for JIA (9) and who had at least two study visits were 
eligible for inclusion in the study. There were no exclusion criteria. Approval from medical ethics 
committees and informed consent from all participants according to the regulations of each 
participating country were obtained.  
 
Functional and clinical disease activity measures 
The validated versions of the HAQ in the Nordic languages were used (8). Scores on a 21-numbered 
circle VAS for physician’s global assessment of disease activity (PhysGA), patient-reported global 
assessment of well-being (PatGA) and patient-reported pain (PatPain) within the last week were 
collected.  On this scale, 0 indicate no activity/no pain/best global health, and 10 indicate the 
maximum activity/worst pain/poorest global health, respectively. The composite juvenile arthritis 
disease activity score (JADAS71) was used (10). The JADAS71 comprises the PhysGA (range 0–10), 
PatGA (range 0–10), active joint count assessed in 71 joints, and the ESR (normalized to 0–10) (9). 
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Definitions of inactive disease and remission 
We adopted the ACR provisional criteria (12) for clinical inactive disease (CID), which includes the 
following: 1) No active joints; 2) no fever, rash, serositis, splenomegaly or generalized 
lymphadenopathy attributable to JIA; 3) no active uveitis; 4) normal ESR and/or CRP; 5) a PhysGA 
that indicates no disease activity and 6) duration of morning stiffness of ≤15 minutes. For CRM, the 
criteria for inactive disease on medication had to be fulfilled for a minimum of 6 continuous months 
(13). To be in CR, patients must have had inactive disease for a continuous period of minimum 12 
months (13) in which they did not receive any anti-arthritis and/or anti-uveitis medication.  
Articular damage and extra-articular damage were scored according to the Juvenile Arthritis Damage 
Indexes (JADI-A and JADI-E, respectively) (14). For the JADI-A, the score for articular damage ranges 
from 0 to 72. The JADI-E encompasses ocular complications, non-articular musculoskeletal damage, 
cutaneous features, endocrine abnormalities, malignancies and secondary amyloidosis (score ranges 
from 0 to 17). 
Normal ESR was defined as a velocity below 20 mm per one hour, and a normal CRP level as below 
10 mg/L 10 (15). Immunofluorescent ANA tests using HEp-2 cells were performed using cut-off 
values for ANA as defined by the individual laboratories at each center.  
 
Statistical analysis 
Descriptive statistics of mean and standard deviation (SD) or median and interquartile range (IQR) 
were used to assess the clinical characteristics and disease activity of the cohort. The chi-squared or 
Fisher´s exact tests were conducted as appropriate, to compare categorical data. The Mann-Whitney 
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RESULTS 
Study population 
This study included 434 (85%) of the 510 eligible participants with JIA onset from 1997 to 2000. The 
follow-up period was 17.5 ± 1.7 years (mean±SD) after onset. The mean age of the study participants 
was 24.0 ± 4.4 years (Table 1); 329 (76%) participants attended a follow-up visit, and 105 (24%) were 
evaluated via telephone interview (Fig 1). At the 18-year follow-up the distribution among the JIA 
categories was:  3.2% systemic, 27.4% persistent oligoarticular, 19.6% extended oligoarticular, 16.4% 
polyarticular RF negative, 1.4% polyarticular RF positive, 6.5% psoriatic, 10.4% enthesitis-related 
arthritis (ERA) and 15.2% undifferentiated JIA (Table 1).  
At the time of inclusion, only 24/434 (6%) were followed at the pediatric clinics, 148/434 (34%) were 
followed by adult rheumatologists and 58% did not have any clinical follow-up owing to their JIA.  
Of the 76 individuals that were lost to follow-up, one died, 7 declined participation and in 68 cases 
the reason was inability to contact them. A comparison of the 76 (15%) participants lost to follow-up 
versus participants included in the follow-up study showed no differences in sex, age at onset, 
number of active joints during the first 6 months after onset, JIA category, CHAQ or JADAS at 
baseline (data not shown). Comparing participants assessed by telephone interview (subjective 
remission) versus participants who underwent clinical examination, the chance of being in remission 
off medication at the last follow-up was twice as high as for those assessed by telephone interview 
(P<0.001).  
 
 Disease activity and damage  
For participants who underwent clinical examination at the 18-year follow-up study, the median 
active joint count was 0 (IQR 0–0). The median cumulative active joint count from inclusion to last 
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PatGA for the overall well-being was 0.5 (IQR 0-2.5). The distribution of scores differed significantly 
between the JIA categories (Table 1). Few participants had elevated inflammatory markers (Table 1).  
Overall, the median JADAS71 was 1.5 (IQR 0-5) (Table 2), and 48% of the patients had a JADAS71 
score <1.  
Morning stiffness more than 15 minutes of duration was found in 67/385 (17%) with the lowest 
proportion in the persistent oligoarticular category (P=0.02). We found 19 cases where the only 
variable indicating active disease was patient-reported morning stiffness of more than 15 minutes 
(Table 4) and they were dispersed in all JIA categories except systemic JIA.  
Articular damage (JADI-A) was seen in 65 (19.8%) of patients at the follow-up visit, while 41 (12.5%) 
had developed extra-articular damage (JADI-E). Ocular damage was the most common extra-
articular damage and was observed in 26/329 (7.9%) of the participants. The polyarticular RF 
negative and psoriatic categories had the highest JADI-A and JADI-E scores (Table 2).  
 
Medication 
Treatments in the first median 12 months after disease onset are listed in table 3. Anytime during 
the disease course 59.7% had been treated with synthetic disease-modifying anti-rheumatic drugs 
(DMARDs) and 29.5% of the participants had been treated with biologics (Table 3). Participants with 
ERA had most often been treated with biologics (23/45 (51%)), and DMARDs were most often used 
in polyarticular RF negative participants (62/71 (87%)). 
 
In total, 189/434 (43.5%) participants had not received any anti-rheumatic treatment in the 
preceding 10 years and the distribution across the JIA categories was: systemic 12/14 (86%); 
persistent oligoarticular 85/119 (71%); extended oligoarticular 19/85 (22%); polyarticular RF 
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arthritis (ERA) 13/45 (29%) and undifferentiated JIA 29/66 (44%). Within the preceding year, 12% 
had received at least one intra-articular corticosteroid injection (IACI). 
At the last follow-up visit 128/434 (29.5%) participants were taking DMARDs (20.0%), biologics 
(19.2%) and/or oral corticosteroids (2.8%)(Table 3). Methotrexate was the most frequently used 
drug, taken by 57 (13.1%) of the participants. At the last visit the proportion of participants with ERA 
(17/45, 37.8%) taking biologics was significantly higher than in the other JIA categories (P=0.01). 
Within the preceding year, 12% of the total cohort had received at least one intra-articular 
corticosteroid injection (IACI).  
Assessing disease status at the study visit revealed that 131 (39.8%) participants had active 
disease of whom 6 (4.6%) were currently taking DMARDs as monotherapy, 46 (35.1%) were 
taking biologics and 30 (22.9%) were taking a combination of DMARDs and biologics. Of all 
the participants who still had active disease, 49 (37.4%) were not taking any medication.  
The main reason for “active disease” was an active joint count of 1. In 9 of the cases the 
active disease was due to morning stiffness (>15 min) as an isolated finding of active 
disease. In two participants active disease was due to unrecognized uveitis flare detected at 
the FU visit and furthermore, two patients reported that medication had been prescribed but 
they refused to take it. 
 
Remission 
Evaluable for the remission status according to the Wallace criteria were the 329 participants of the 
cohort that attended a clinical visit. The medical history including the treatment within the previous 
year was cross-checked with the information in the records for the majority of the participants 
(301/329; 91%). At the final follow-up visit we found that 150 (45.6%) had active disease and did not 
fulfil the ACR provisional criteria for inactive disease 12 (Table 4). Active disease was observed in all 
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proportion with active disease in the ERA category was 64.9%, the highest proportion found in all 
the categories (Fig 2) even though biologic medication was most frequently used in ERA (37.8%). 
More than half of the participants with psoriatic arthritis had active disease, while only 3 (10.7%) 
were on biologics (data not shown). If morning stiffness ≤15 minutes was not included as a criterium 
for inactive disease as in Wallace’ preliminary 2004 criteria, only 131 (39.8%) participants would 
have qualified for an active disease status (Table 4). 
Complete remission off medication (CR) was observed in 108/329 (32.8%) of the participants who 
had a clinical examination at the last follow-up (Table 4). Another 33 participants (10%) were in 
remission on medication for at least 6 months and 38 (11.6%) were having inactive disease although 
not yet fulfilling Wallace’ preliminary remission criteria with respect to the duration of inactive 
disease. The persistent oligoarticular and systemic JIA categories had the highest proportions of CR 
(54.2% and 53.8%, respectively) and the lowest proportion of CR was found in the ERA category 
(8.1%) being significantly lower than in the other categories (Fig.1, P<0.001).  
If we included the telephone-interviewed participants and accepted the participants’ own 
judgement of having inactive disease, the proportion of CR was 186/423 (44.0%) (Table 4). 
 
DISCUSSION 
To date, this is the largest close to population-based study to investigate the long-term outcome 
in JIA in the transition from pre-biologic to biologic era. In the Nordic countries biological therapy 
was introduced in 1999 and 2000, which means that for most of the patients included in this 
study biologics were not available at the very beginning of their disease course. Although 94% 
were no longer followed at the pediatric departments we were able to include 85% of this 
prospectively included, non-selected JIA cohort 18 years after disease onset, and more than three 
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Our results confirm the conceptual knowledge of JIA as a chronic disease since only 33% of the 
JIA participants were in complete remission for at least 12 months off medication (CR) 18 years 
after disease onset. Further, more than 45% of the cohort had active disease even 18 years after 
disease onset. However, our results show that the vast majority of patients with active disease 
were in the very mild range of the activity scale and many of the patients even had such a mild 
disease activity that medication was considered unnecessary. 
Disease status varied extensively according to the JIA categories. CR was most often seen in 
participants with persistent oligoarticular and systemic JIA and was least often seen in ERA. 
As a comparison, Selvaag et al. reported a higher number of participants in CR (59%) and fewer with 
active disease (34%) in their 30-year prospective, longitudinal follow-up study in Norway from the 
pre-biologic era (3). However, only half of the participants underwent clinical examination selected 
from an initial questionnaire if they were on medication or had patient-reported signs of disease 
activity. It is conceivable that the high number of participants not evaluated clinically would have 
increased the rate of CR as this was also the case for the group of participants in our study that were 
evaluated by telephone interview.  Selvaag et al. also reported that the systemic and oligoarticular 
category of JIA had the highest remission rate; and as in our study, the lowest remission rate was 
seen in the RF positive polyarticular and the ERA categories.  
Bertilsson and colleagues conducted a population-based cohort study in the pre-biologic era and 
found that 17 years after disease onset, only 2% of the participants had active disease, while 40% 
were in remission. However, this study used the European League Against Rheumatism (EULAR) 
diagnostic criteria for Juvenile Chronic Arthritis (JCA) and RA disease activity/remission criteria (16).  
In our study 29.5% of the participants remained on DMARDs and/or biologics at follow-up, indicating 
that there is still a high disease burden even 18 years after disease onset. This is consistent with the 
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We applied the 2011 ACR definition of CID (12), which includes morning stiffness and found that in 
6% of the cohort with active disease, this disease status was exclusively based on morning stiffness. 
This variable may indicate some level of disease activity not captured by the physicians or blood 
samples in adult JIA patients. Taking morning stiffness into account in contrast to the preliminary 
Wallace criteria (13) have skewed our data towards a higher proportion with active disease.  
Although, the role of morning stiffness in disease activity has been debated in previous reports in RA 
patients (18,19) we found that baseline morning stiffness is an important predictor of not being in 
remission 8 years after disease onset (20). However, it is important to acknowledge that there are 
insufficient data to optimally measure morning stiffness and its role in the spectrum of CID and 
remission in RA, and data on adult JIA patients has not been studied (21,22).  
Unexpectedly, only 42% were followed by a physician or rheumatologist although almost 46% had 
active disease at last follow-up. This indicates that some of the participants might be lost to follow-
up after transfer to adult care even in government-funded health care systems with minimal out-of-
pocket co-payments. 
To our surprise 37% of the participants with active disease did not receive any systemic treatment. 
Of these, 19% had morning stiffness more than 15 minutes, which was registered as the only sign of 
active disease and was deemed not requiring any systemic treatment. In two other cases it was due 
to unrecognized flare of their uveitis, and furthermore few participants had medication prescribed 
but did not take it. One might think that minor disease activity such as a flare with synovitis only in a 
knee would preferably be treated with an intra-articular corticosteroid injection rather than with 
systemic treatment. 
When looking back at the treatment during the preceding 10 years more than 40% had not received 
any anti-rheumatic treatment indicating that the disease was not present anymore. This was least 
often observed in the extended oligoarticular category.  
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evaluate long-term outcome in a non-selected JIA cohort. The percentage of participants lost to 
follow-up is acceptable (15%) and is less than in other long-term outcome studies (3,17). We used 
validated outcome measures, and the entire cohort was invited to attend a clinical visit regardless of 
disease status with a high proportion of respondents. Further, the genetic variability of the 
participants in this study is rather low with >95% being Caucasians.  
For the achievement of an inactive disease status end-scale avoidance may play an important role 
when reporting the PhysGA, skewing the score towards a more active disease course. This challenge 
has also been addressed by Filocamo et al. (23) and other studies have used PhysGA <10 mm as the 
lower limit of inactive disease to avoid the skewness (1,24). 
One limitation of this study may be the validity of data collected by telephone interview. For this 
reason, we chose to report remission data for participants that attended a clinical visit separately in 
order to improve the validity of the data. We found significantly more participants in remission 
(subjective remission) based on participant´s answers by telephone survey compared to CR in the 
group attending a clinical visit (P<0.001). This is an uncertain measure, as we do not have a joint 
count and inflammatory biomarkers (ESR) from individuals participating in the telephone survey 
only. Nevertheless, one could speculate that specifying the disease status exclusively among the 
participants attending a clinical visit has skewed the remission data for that group towards worse 
outcomes. 
Still, 65% of the eligible cohort was evaluated by clinical examination compared to 35% in a previous 
Norwegian study (2). 
JIA has a fluctuating disease course, and it is a limitation of our study that we did not report data 
between 8 and 18 years of follow-up. In addition, the inclusion period was at the very beginning of 
the biologic era (25), indicating that few of the participants received early biologic treatment. 
Treatment guidelines (26,27) have changed during the last two decades, but there is still a need for 
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treatment traditions among the centers in the Nordic countries are fairly homogeneous, it cannot be 
excluded that individual interpretations of treatment strategies of the participating centers might 
have affected the long-term outcomes.  
In summary, this study found a substantial prevalence of ongoing active disease and a high burden 
of medication and damage in JIA even 18 years after disease onset. Notably, the ERA category of JIA 
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FIGURE LEGENDS 
Figure 1 Flow-chart of the study population. F=female, M=male. 
  
Figure 2 Disease status in JIA 18 years after disease onset (n=329). 
Systemic, systemic juvenile idiopathic arthritis; Oligoarticular persist, persistent oligoarticular; Oligo 
ext, extended oligoarticular; PolyRF pos, polyarticular RF positive; PolyRF neg, polyarticular RF 
negative; Psoriatic, psoriatic arthritis; ERA, enthesitis-related arthritis; Undiff, undifferentiated 
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 n (%)  434  14 (3.2%) 119 (27.4%) 85 (19.6%) 71 (16.4%) 6 (1.4%) 28 (6.5%)  45 (10.4%) 66 (15.2%) 
Females, n (%) 434 297(68.4) 9 (64.3) 79 (66.3) 67 (78.8) 52 (73.2) 5 (83.3) 20 (71.4) 14 (31.1) 51 (77.3) 
Age at onset, years 432 6.5±4.1 6.5±4.5 5.7±3.7 4.9±3.7 5.7±4.0 11.1 ±2.1 7.3 ±4.2 9.4±3.6 7.8±4.2 
Age at follow-up, years,  434 23.9 ±4.4 24.6 ±4.6 23.5 ±4.0 22.4 ±4.0 22.9 ±4.4 28.7 ±1.8 25.1 ±4.5 26.9 ±4.0 24.6 ±4.6 
Disease duration, years,  431 17.5 ±1.7 18.0 ±0.7 17.7 ±1.1 17.5 ±1.4 17.2 ±1.2 17.8 ±0.9 17.4 ±1.0 17.5 ±2.5 17.2 ±2.7 
CRP >10 mg/L,n (%) 328 16 (4.9) 0 (0.0) 2 (2.7) 3 (4.8) 3 (5.0) 0 (0.0) 2 (8.3) 4 (10.5) 2 (3.8) 
ESR >20 mm/h,n (%) 282 19 (6.7) 0 (0.0) 3 (5.0) 3 (5.5) 3 (5.5) 0 (0.0) 3 (12.5) 4 (12.5) 3 (7.0) 
ANA positive, n (%) 303 92 (30.4) 3 (27.3) 18 (26.9) 22 (39.3) 16 (28.1) 2 (50.0) 6 (24.0) 9 (25.0) 16 (34.0) 
HLA-B27 positive, n (%) 409 93 (22.7) 2 (15.4) 12 (11.1) 10 (12.7) 10 (14.1) 1 (16.7) 5 (18.5) 35 (79.5) 18 (27.3) 
PhysGA VAS,  
median (IQR) 
328 0 (0–1.0) 0 (0–0) 0 (0–0) 0 (0–1.5) 0 (0–1.0) 0 (0–2.0) 0 (0–1.0) 1.0 (0–2.5) 0 (0–2.0) 
PatGA VAS, 
median (IQR)§ 
404 0.5 (0–2.5) 0 (0–0.5) 0 (0–1.5) 0.8 (0–2.5) 0.5 (0–2.3) 1.5 (0-5.5) 1.0 (0–2.5) 1.5 (5–4.0) 1.0 (0–4.0) 
PatPain VAS,  
median (IQR)§ 
404 0.6 (0–3.0) 0 (0–0.5) 0 (0–1.5) 1.0 (0–4.0) 1.0 (0–27.5) 2.0 (0–6.0) 0.5 (0–4.0) 1.0 (0–3.0) 1.5 (0–4.0) 
Morning stiffness 
≥ 15 min., n (%) 
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The second column shows the number of patients that were assessed at the final study visit. Age and disease duration are expressed as mean of yearsSD. 
PhysGA VAS, physician global assessment of disease activity on a visual analogue scale; PatGA, patient global assessment of overall well-being; PatPain, 
patient reported rating of intensity of pain. §Statistically significant differences between JIA categories; P=0.015 for PatPain and P<0.001 for PatGA. IQR, 1st 
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Values are expressed as median (1st -3rd interquartile range (IQR)), unless otherwise expressed. The second column indicates the number of patients that 
were assessed at the final clinical visit. LOM, limitation on motion, ERA, enthesitis-related arthritis, *JADAS71, juvenile arthritis disease activity score based 
on evaluation of 71 joints, **JADAS71 ≤1 indicates inactive disease according to Consolaro et al (13).  JADI-A, Juvenile Arthritis Damage Index-articular; 
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Table 3 Status of the medical therapy according to JIA category in the Nordic JIA cohort at the 18-
year follow-up visit. 
 Total 
cohort  
























































































































41 (9.4) 0 (0.0) 7 (5.6) 9 (10.6) 11 (15.5) 1 (16.7) 5 (17.9) 4 (22.5) 4 (6.1) 
Monotherapy 
biologics***  
at last FU 
38 (8.8) 0 (0.0) 3 (2.5) 8 (9.4) 6 (8.5) 1 (16.7) 2 (7.1) 9 (20.0) 9 (13.6) 
Biologics + 
DMARDs  
at last FU 
46 (10.6) 2 (14.3) 4 (3.4) 11 (12.9) 16 (22.5) 0 (0.0) 1 (3.6) 8 (17.8) 4 (6.1) 
Systemic 
corticosteroids 
at last FU 
12 (2.8) 0 (0.0) 1 (0.8) 1 (1.2) 6 (8.5) 0 (0.0) 0 (0.0) 3 (6.7) 1 (1.5) 
No medication 
at last FU**** 
306 (70.5) 12 (85.7) 103 (86.6) 59 (69.4) 39 (54.9) 4 (66.7) 23 (82.1) 22 (48.9) 49 (74.2) 
Joint injection 
within the last 
year 
52 (12.0) 0 (0.0) 7 (5.9) 15 (17.6) 11 (15.5) 0 (0.0) 3 (10.7) 6 (13.3) 10 (15.2) 
 
Values indicate the number of patients, with percentage in brackets. FU, follow-up. ERA, enthesitis-
related arthritis. * The disease-modifying antirheumatic drugs (DMARDs) and biologics used during 
median 12 months after onset in the categories at that time point. **DMARDs included 
methotrexate, azathioprine, hydroxychloroquine, leflunomide, sulfasalazine and mycophenolate 
mofetil. ***The biologic drugs included etanercept, infliximab, adalimumab, certolizumab, 
golimumab, rituximab, abatacept, anakinra, canakinumab, rilonacept and tocilizumab. ****Off all 
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Table 4 Remission status of participants attending a clinical visit and/or including the interviewed 
participants in the Nordic JIA cohort at the 18-year follow-up based on Wallace´s preliminary and 
ACR provisional criteria for the definition of inactive disease. 
 
 According to the 
preliminary criteria 13 
(visit) 
According to the ACR 
provisional criteria 12 
(visit) 
 According to the 
preliminary criteria13  
(visit + interview) 
Active disease 131 (39.8±5.3) 150 (45.6±5.4)  140 (33.1±4.5) 
Remission on medication 37 (11.2±5.4) 33 (10.0±3.2)  40 (9.5±2.8) 
Remission off medication 116 (35.3±5.2) 108 (32.8±5.1)  186 (44.0±4.7) 













Values in brackets are expressed as percentages of each subcategory with 95% CI.  
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